Tampa health care technology service acquires Jacksonville company
HealthAxis Group, a Tampa-based health technology service, has acquired a Jacksonville firm that develops and implements data warehouse and business intelligence solutions. Terms of the acquisition of Analytics Partners were not disclosed. The merger of the companies business operations adds “robust and proven analytics to complement the HealthAxis Group's current and powerful core platform and services,” according to a statement from HealthAxis. HealthAxis Gr oup acquired Analytics Partners’… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 19, 2019 Category: American Health Authors: Crystal Owens Source Type: news

Tampa health care technology service acquires Jacksonville company
HealthAxis Group, a Tampa-based health technology service, has acquired a Jacksonville firm that develops and implements data warehouse and business intelligence solutions. Terms of the acquisition of Analytics Partners were not disclosed. The merger of the companies business operations adds “robust and proven analytics to complement the HealthAxis Group's current and powerful core platform and services,” according to a statement from HealthAxis. HealthAxis Gr oup acquired Analytics Partners’… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 19, 2019 Category: Biotechnology Authors: Crystal Owens Source Type: news

Intuitive Falls Short of Expectations in 1Q19
Intuitive Surgical’s momentum was dulled a bit last week when the surgical robotics company missed Wall Street expectations for 1Q19. The miss caused shares of the Sunnyvale, CA-based company to drop by about 6.2%. Intuitive’s revenue came in at about $973.7 million for the quarter, with analysts forecasting $980 million in 1Q19 sales. The company also posted earnings of $2.61 per share, on an adjusted basis. Earnings grew 7% but decelerated from 20% growth in the fourth quarter. The earnings also lagged the consensus of analysts polled by analysts for $2.70. One of the companyâ...
Source: MDDI - April 19, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Proteon exploring sale after 2nd drug trial failure
Cash-strapped biotech Proteon Therapeutics is considering a merger or acquisition after shelving its lead kidney disease drug due to a second late-stage clinical trial failure. Waltham-based Proteon (Nasdaq: PRTO) disclosed in a financial filing this week that it does not have enough cash to survive for the next 12 months, with just $22 million left in the bank. Four members of the company's board of directors further resigned this week. It will be laying off an undisc losed amount of its 17 employees… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 19, 2019 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Abbott Has Midas Touch with Its 1Q19 Earnings
Abbott Laboratories is off to a solid start in 2019 if its most recent earnings are any indication. The Abbott Park, IL-based company reported earnings that topped its own forecast. The firm posted first-quarter earnings from continuing operations of 63 cents per share, above the 61 cents expected by analysts, on $7.5 billion in sales. "We're right on track with our expectations to start the year," said Miles White, chairman and CEO, Abbott, said in a release. "All of our key long-term growth drivers are performing well and we're targeting another year of strong sales and earnings growth." Join us for N...
Source: MDDI - April 17, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Eritrea: Cervical Cancer Prevention and Control Program Implementation in Eritrea
[WHO] Cervical cancer occurs when the cells of the cervix grow abnormally and invade other tissues and organs of the body. When it is invasive, this cancer affects the deeper tissues of the cervix and may have spread to other parts of the body. Cervical cancer is caused through acquisition of HPV virus (Human Papillomavirus) when a woman is sexually active and the virus has been acquired. Some women then develop pre cancer lesions but in about 66% to 70% of these women, the body normally clears it away. However, (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 17, 2019 Category: African Health Source Type: news

UnitedHealth: DaVita Medical Deal ‘Progressing’ On Path To Close
UnitedHealth Group CEO David Wichmann says the insurer has a " clear path to approval " in closing the $4.3 billion acquisition of DaVita Medical Group. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 17, 2019 Category: Pharmaceuticals Authors: Bruce Japsen, Contributor Source Type: news

Able & Co. Celebrates Tenth Year With Spacious New Location and...
Expertise in marketing for mergers, acquisitions, and franchises fuels growth(PRWeb April 17, 2019)Read the full story at https://www.prweb.com/releases/able_co_celebrates_tenth_year_with_spacious_new_location_and_expanded_staff/prweb16102646.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 17, 2019 Category: Pharmaceuticals Source Type: news

Lawsuits Put a Drag on J & amp;J 1Q19 Earnings
Legal costs surrounding Johnson and Johnson’s talc baby power and its blood thinner Xarleto bogged down the healthcare giant’s 1Q19 earnings. But while earnings from the New Brunswick, NJ-based company were down 14% from a year earlier, the firm managed to beat analyst expectations. J&J posted income of $3.75 billion or $1.39 per share for 1Q19. In 1Q18, the company brought in $4.37 billion or $1.60 per share. As a result, the healthcare company changed its full-year earnings forecast to a range of $8.53 to $8.63 a share, down from its previous estimate of between $8.50 and $8.65. Th...
Source: MDDI - April 16, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Biotech with large Triangle presence buying Maryland firm for $1.2B
Catalent Inc., a New Jersey-based contract drug manufacturer with a large Triangle presence, said Monday it will acquire Maryland's Paragon Bioservices Inc. for $1.2 billion. Catalent (NYSE: CTLTC) will fund the acquisition using the proceeds of a $650 million incremental term loan from JPMorgan Chase Bank, as well as the issuance of $650 million of new convertible preferred stock to Leonard Green& Partners L.P. Peter Zippelius, a partner at LGP, will join Catalent ’s board of directors as part… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 16, 2019 Category: Health Management Authors: Morgan Eichensehr Source Type: news

Patch Offers a New Approach for Treating Iron Deficiency
Patch-like wearables are becoming increasingly popular in medtech. The latest device to employ such a design and make medtech headlines is transdermal patch being developed by Fe3 Medical. San Antonio, TX-based Fe3 said its biphasic iontophoretic transdermal technology is for the treatment of iron deficiency anemia. The firm announced results from its first human study of the patch-like device. The human study focused on the safety and tolerability of Fe3's iontophoretic transdermal technology designed to bypass ionic resistance build up in the skin. The human study follows a series of successful preclinical studies demons...
Source: MDDI - April 15, 2019 Category: Medical Devices Authors: Omar Ford Tags: Adhesives Source Type: news

New Jersey drug maker to buy Maryland's Paragon Bioservices for $1.2B
Catalent Inc., a New Jersey-based contract drug manufacturer, said Monday it will acquire Maryland's Paragon Bioservices Inc. for $1.2 billion. Catalent (NYSE: CTLTC) will fund the acquisition using the proceeds of a $650 million incremental term loan from JPMorgan Chase Bank, as well as the issuance of $650 million of new convertible preferred stock to Leonard Green& Partners L.P. Peter Zippelius, a partner at LGP, will join Catalent ’s board of directors as part of the new investment. The all-cash… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 15, 2019 Category: American Health Authors: Morgan Eichensehr Source Type: news

Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare, positioning Catalent for accelerated long-term growth SOMERSET, N.J. and BALTIMORE, April 15, 2019 -- (Healthcare Sales & Marketing Network) -- Catalent, Inc... Biopharmaceuticals, Mergers & Acquisitions Paragon Bioservices, Catalent (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 15, 2019 Category: Pharmaceuticals Source Type: news

Programming a CDASH-Compliant eCRF Library with Biostatistics,...
Clinical Data Acquisition Standards Harmonization (CDASH) outlines best practices for presenting data to maintain consistency and quality across different trial phases and therapeutics areas. In this...(PRWeb April 15, 2019)Read the full story at https://www.prweb.com/releases/programming_a_cdash_compliant_ecrf_library_with_biostatistics_upcoming_webinar_hosted_by_xtalks/prweb16241985.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 15, 2019 Category: Pharmaceuticals Source Type: news

Obalon Explores Financial and Strategic Alternatives
Obalon Therapeutics said it has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alternatives. The move comes about a week after the San Diego-based company announced a restructuring measure that would see it cut half of its workforce. The obesity-treatment specialist said the bulk of the cuts would come from it eliminating its salesforce and switching to a new sales model. Obalon said with Cowen’s assistance it plans to explore a wide range of financial and strategic alternatives that could enhance stockholder value and enable the company to continue servi...
Source: MDDI - April 12, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

BMS shareholders approve Celgene megadeal
Bristol-Myers Squibb shareholders approved the company ’s $74 billion acquisition of rival Celgene, despite activist campaigns to break up the deal. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 12, 2019 Category: Pharmaceuticals Source Type: news

Bristol-Myers Squibb shareholders approve Celgene acquisition
Bristol-Myers Squibb Company (NYSE: BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company's pending merger with Celgene Corporation (NASDAQ:CELG) at the Special Meeting of Stockholders. (Source: World Pharma News)
Source: World Pharma News - April 12, 2019 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Obalon taps Cowen to explore ‘ strategic alternatives ’
Obalon Therapeutics (NSDQ:OBLN) today tapped an advisory firm to explore “strategic alternatives,” a week after revealing plans to cut its workforce in half. The Carlsbad, Calif.-based company, which makes a gas-filled balloon designed to treat obesity, said April 3 that it would lay off 49 of its 100 employees, including all of its direct sales force, in a pivot toward retail. Today the company said it hired investment bank Cowen “as an independent financial advisor to assist in exploring financial and strategic alternatives” to explore “a wide range of financial and strategic alternativ...
Source: Mass Device - April 11, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Business/Financial News Mergers & Acquisitions Wall Street Beat Weight loss Obalon Therapeutics Source Type: news

BDSI expects $50 million in latest public offering
Following the announcement of the $30 million acquisition of U.S. commercialization rights to a Japanese drug, Raleigh's BDSI has priced its public offering – anticipating gross proceeds of $50 million. BioDelivery Sciences International, (Nasdaq: BDSI) recently announced the acquisition of exclusive U.S. commercial rights for Shionogi's Symproic – a drug which treats opioid-induced constipation in adult patients with chronic non-cancer pain. T he rights will cost the company $20 million… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 11, 2019 Category: Health Management Authors: Seth Thomas Gulledge Source Type: news

BDSI announces public offering after paying $30M for drug rights
In a pair of announcements, Raleigh's BioDelivery Sciences International (Nasdaq: BDSI), announced the $30 million acquisition of exclusive U.S. commercialization rights to a Japanese drug. In the hours following that deal, BDSI also announced a public offering of its common stock. Made by Shionogi, the drug – called Symproic – treats opioid-induced constipation in adult patients with chronic non-cancer pain. BDSI will pay Shionogi $20 million upfront and another $10 million on the six-month… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 11, 2019 Category: Pharmaceuticals Authors: Seth Thomas Gulledge Source Type: news

Evidence for hormonal control of heart regenerative capacity during endothermy acquisition
Tissue regenerative potential displays striking divergence across phylogeny and ontogeny, but the underlying mechanisms remain enigmatic. Loss of mammalian cardiac regenerative potential correlates with cardiomyocyte cell-cycle arrest and polyploidization as well as the development of postnatal endothermy. We reveal that diploid cardiomyocyte abundance across 41 species conforms to Kleiber’s law—the 3/4-power law scaling of metabolism with bodyweight—and inversely correlates with standard metabolic rate, body temperature, and serum thyroxine level. Inactivation of thyroid hormone signaling reduces mouse c...
Source: ScienceNOW - April 11, 2019 Category: Science Authors: Hirose, K., Payumo, A. Y., Cutie, S., Hoang, A., Zhang, H., Guyot, R., Lunn, D., Bigley, R. B., Yu, H., Wang, J., Smith, M., Gillett, E., Muroy, S. E., Schmid, T., Wilson, E., Field, K. A., Reeder, D. M., Maden, M., Yartsev, M. M., Wolfgang, M. J., Gru&#x Tags: Development, Evolution reports Source Type: news

TAVR Puts the Swagger Back in Mick Jagger
Rolling Stones frontman Mick Jagger’s recent surgery is putting a huge spotlight on the transcatheter aortic valve replacement (TAVR) market. Late last week, Jagger tweeted that his procedure was a success and thanked fans for their support.   Thank you everyone for all your messages of support, I’m feeling much better now and on the mend - and also a huge thank you to all the hospital staff for doing a superb job. — Mick Jagger (@MickJagger) April 5, 2019 Problems for the 75-year-old began late last month after the rocker fell ill. As a result, the Rolling...
Source: MDDI - April 10, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news

Admedus deals vaccines biz to Constellation Therapeutics
Admedus (ASX:AHZ) said today that it agreed to sell its vaccines business to Constellation Therapeutics in a deal that will see it own nearly 30% of the Chinese company. Other shareholders in the vaccines would own another 11%, Queensland, Australia-based Admedus said. Sun Bright Holdings will own the remainder and put in $18 million until November 2022, in five $3.6 million installments pegged to “certain milestones,” the company said. Failure to pay an installment would trigger the conversion of 12% of Constellation shares to the Admedus bloc of vaccine business shareholders. Admedus CEO Wayne Patte...
Source: Mass Device - April 10, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Featured Mergers & Acquisitions Regenerative Medicine Wall Street Beat Admedus Ltd. Source Type: news

FTC grants final approval for Fresenius ’ s $2B buyout of NxStage
The U.S. Federal Trade Commission said yesterday that it granted a final order of approval to Fresenius Medical Care (NYSE:FMS; ETR:FRE) for its $2 billion acquisition of NxStage Medical. The approval came with a caveat that the companies divest their assets and rights to research, develop, manufacture, market and sell NxStage’s bloodline tubing sets intended for use during hemodialysis treatment. To mollify the anti-trust regulators, NxStage last July agreed to deal its Medisystems bloodlines business to B. Braun. The final order was approved in a three-to-two vote, according to an FTC posti...
Source: Mass Device - April 10, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Dialysis Featured Mergers & Acquisitions Wall Street Beat Fresenius NxStage Medical Inc. Source Type: news

Pathology contract extended amid merger doubts
A trust has extended its pathology contract with a public-private partnership as doubts have emerged over a planned merger with a neighbour. (Source: HSJ)
Source: HSJ - April 10, 2019 Category: UK Health Source Type: news

MYRX365 Announces Acquisition of RealTime Clinic
Tech-Enabled Pharmacy Company, MYRX365, to Drive Prescription Adherence and Engagement via its Combined Technologies.(PRWeb April 10, 2019)Read the full story at https://www.prweb.com/releases/myrx365_announces_acquisition_of_realtime_clinic/prweb16229929.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 10, 2019 Category: Pharmaceuticals Source Type: news

These 10 VC-backed companies scored the biggest Bay Area exits in Q1
First quarters are often slow times for initial public offerings and acquisitions, but this year's was hampered even further by the longest federal government shutdown in U.S. history, a hiatus that delayed regulatory action on deals. The number of Bay Area exits via IPOs and M&A in the first quarter dropped sharply to 40, according to PitchBook Data. That marks less than half the total from last year's first quarter. Things started to pick up after the federal government shutdown ended, with all… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 10, 2019 Category: Biotechnology Authors: Cromwell Schubarth Source Type: news

These 10 VC-backed companies scored the biggest Bay Area exits in Q1
First quarters are often slow times for initial public offerings and acquisitions, but this year's was hampered even further by the longest federal government shutdown in U.S. history, a hiatus that delayed regulatory action on deals. The number of Bay Area exits via IPOs and M&A in the first quarter dropped sharply to 40, according to PitchBook Data. That marks less than half the total from last year's first quarter. Things started to pick up after the federal government shutdown ended, with all… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 9, 2019 Category: American Health Authors: Cromwell Schubarth Source Type: news

Osso VR Brings Surgical Training Tech to Europe
A fast-growing company known for its virtual reality surgical training program has expanded into the European market. Newcastle Hospital's simulation center has already begun using Osso VR's technology to prepare surgeons for difficult procedures. The European healthcare market is facing growing challenges training new surgeons. According to a report from the Royal College of Surgeons, surgical trainees were focused more on service tasks, such as administrative work, instead of participating in patient care. Additionally, changing dynamics within training have resulted in les...
Source: MDDI - April 9, 2019 Category: Medical Devices Authors: MD+DI Staff Tags: Digital Health Source Type: news

Home care agency to lay off 200 after Wellforce merger
After joining with Tufts Medical Center parent Wellforce, a hospice and home care company will shutter one of its agencies, laying off 217 people. Home Health Foundation joined Wellforce in June 2018, bringing its three agencies — skilled nursing company Home Health VNA, hospice company Merrimack Valley Hospice, and non-clinical support services company Home Care Inc. into the Wellforce brand. But Home Health said it will shutter HomeCare on June 3 as it refocuses exclusively on clinical services. “Over… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 9, 2019 Category: Pharmaceuticals Authors: Jessica Bartlett Source Type: news

Recruiting people to upstate can be hard, so this physician group created a team to make it easier
Community Care Physicians P.C. started its talent acquisition team after consolidating with CapitalCare to form the third-largest physician group in the area. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 9, 2019 Category: Pharmaceuticals Authors: Liz Young Source Type: news

Histogenics to merge with Ocugen
Histogenics (NSDQ:HSGX) said yesterday that it inked a definitive merger agreement with Ocugen through which both companies will combine into a single publicly-traded, clinical-stage biopharmaceutical company. The combined entity will operate under the Ocugen name, the companies said. As part of the deal, Ocugen’s shareholders will become the majority owners of Histogenics outstanding common stock upon the closure of the merger. Read the whole story on our sister site, Drug Delivery Business News (Source: Mass Device)
Source: Mass Device - April 9, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured Mergers & Acquisitions Wall Street Beat Histogenics ocugen Source Type: news

Silk Road Medical clears $109m in IPO
Silk Road Medical (NSDQ:SILK) said yesterday that it cleared just more than $109 million in its initial public offering, including a fully subscribed underwriters option. The $20-per-share flotation grossed $120 million, Sunnyvale, Calif.-based Silk Road said. The company is developing a neuroprotection and stent system called Enroute as an aid to transcarotid artery revascularization procedures. Silk Road’s estimated net proceeds of $109.1 million are earmarked for sales force expansion, new clinical trials, increasing its international footprint and potentially for acquisitions. president & CEO Erica Roger...
Source: Mass Device - April 9, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Featured Funding Roundup Neurological Wall Street Beat Silk Road Medical Inc. Source Type: news

Canadian company that owns Ruskin cannabis farm acquired for $41.2 million
A Toronto global cannabis company completed its acquisition of  the corporation that owns Ruskin-based 3 Boys Farms LLC in a $41.2 million cash and stock deal. The July 2018 agreement between SOL Global Investments Corp. and CannCure Investments, a privately-held Ontario company that owns 3 Boys Farms, was partially satisfied with the release of 7.3 million common shares of SOL Global’s stock at $4 per share to CannCure on a proportional basis. The terms of the acquisition say that if SOL Global… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 9, 2019 Category: American Health Authors: Crystal Owens Source Type: news

The first decade of web-based sports injury surveillance: descriptive epidemiology of injuries in US high school boys' baseball (2005-2006 through 2013-2014) and National Collegiate Athletic Association men's baseball (2004-2005 through 2013-2014) - Wasserman EB, Sauers EL, Register-Mihalik JK, Pierpoint LA, Currie DW, Knowles SB, Dompier TP, Comstock RD, Marshall SW, Kerr ZY.
CONTEXT: The advent of Web-based sports injury surveillance via programs such as the High School Reporting Information Online system and the National Collegiate Athletic Association Injury Surveillance Program has aided the acquisition of boys' and men's b... (Source: SafetyLit)
Source: SafetyLit - April 8, 2019 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

The first decade of web-based sports injury surveillance: descriptive epidemiology of injuries in US high school girls' softball (2005-2006 through 2013-2014) and National Collegiate Athletic Association women's softball (2004-2005 through 2013-2014) - Wasserman EB, Register-Mihalik JK, Sauers EL, Currie DW, Pierpoint LA, Knowles SB, Dompier TP, Comstock RD, Marshall SW, Kerr ZY.
CONTEXT: The advent of Web-based sports injury surveillance via programs such as the High School Reporting Information Online system and the National Collegiate Athletic Association Injury Surveillance Program has aided the acquisition of girls' and women'... (Source: SafetyLit)
Source: SafetyLit - April 8, 2019 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Final defendant sentenced in insider trading case
Federal prosecutors have wrapped up an insider trading case based on alleged tips from a Bank of America consultant on pending corporate transactions, including Abbott‘s (NYSE:ABT) $25 billion acquisition of St. Jude Medical. Rodolfo Sablon, 39, of Miami, Fla., was sentenced Friday to six months in prison for his role in the insider trading scheme based on tips from Bank of America technical consultant Daniel Rivas. U.S. District Judge Alison Nathan also sentenced Sablon to two years of supervised release, including six months in a community confinement center, and ordered him to pay $923,566 in forfeiture and a...
Source: Mass Device - April 8, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Business/Financial News Featured Legal News Mergers & Acquisitions News Well Wall Street Beat Abbott st.judemedical Source Type: news

Histogenics to serve as shell for Pennsylvania biotech in reverse-merger
Beleaguered cell therapy firm Histogenics Corp., which has appeared headed toward bankruptcy or a shutdown in recent months, announced Monday that it will be absorbed by a private Pennsylvania biopharma. Histogenics (Nasdaq: HSGX) has signed a reverse-merger with rare eye disease company Ocugen Inc., through which the privately held company will go public, according to a press release. The new company will move forward with Ocugen's name and headquarters, and no Histogenics employees will have job s… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 8, 2019 Category: Health Management Authors: Allison DeAngelis Source Type: news

Malvern gene therapy developer to acquire publicly traded Boston company
Ocugen Corp., a Malvern-based gene therapy and biopharmaceutical company developing new treatments for rare and underserved eye diseases, entered into a merger agreement Monday with Histogenics Corp., a publicly traded company based in Boston Under the terms of the stock-for-stock agreement, the stockholders of Ocugen will own about 90 percent of Histogenics’ outstanding common stock once the deal closes. Shareholders of Histogenics — which began Monday with a market cap of $10.5 million —… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 8, 2019 Category: Pharmaceuticals Authors: John George Source Type: news

SHO Products Raises $3.6 Million in Series A Funding Round
Capital Infusion Will Enable SHO To Rapidly Scale Talent and To Increase Growth Through Acquisitions(PRWeb April 08, 2019)Read the full story at https://www.prweb.com/releases/sho_products_raises_3_6_million_in_series_a_funding_round/prweb16223471.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 8, 2019 Category: Pharmaceuticals Source Type: news

17 digital health mergers and acquisitions from the first quarter of 2019
From market consolidation to global expansions, the quarter saw a range of interesting deals. (Source: mobihealthnews)
Source: mobihealthnews - April 5, 2019 Category: Information Technology Source Type: news

Boehringer Ingelheim enhances oncology R & D with novel MacroDel delivery technology via acquisition of ICD Therapeutics
Boehringer Ingelheim announced that it acquired ICD Therapeutics. The acquisition includes rights to ICD's innovative MacroDel biologics-delivery platform. Boehringer Ingelheim will employ this platform for the development of novel therapeutics in collaboration with nanoPET Pharma GmbH, a former shareholder of ICD Therapeutics. (Source: World Pharma News)
Source: World Pharma News - April 5, 2019 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Seisa Medical acquires stent & delivery system maker Burpee MedSystems
Seisa Medical said today that it acquired stent and delivery device manufacturer Burpee MedSystems for an undisclosed amount. New Jersey-based Burpee MedSystems was founded in 1998 and uses laser machining, surface finishing, nitinol forming and shaping and welding to create stents and delivery systems, El Paso, Texas-based Seisa Medical said. “We are thrilled to be joining Seisa as it gives Burpee MedSystems the global infrastructure we’ve been aiming for to expand our offerings and capabilities to the market,” Burpee MedSystems CEO Janet Burpee said in a prepared statement. Janet and co-founder Steve Bu...
Source: Mass Device - April 4, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Stents seisamedical Source Type: news

Catapult, Smithwise slated to merge
Medical device development firms Catapult Product Development and Smithwise have agreed to merge. Founded in 2012, Catapult is a full-service medical device development firm, specializing in console-based diagnostic and therapeutic systems, minimally-invasive surgical and diagnostic tools, and an array of portable and handheld medical equipment. The Waltham, Mass.-based company works extensively with startups to enable their core technologies, and with established device manufacturers and academic centers as they accelerate device development projects toward commercialization. Get the full story on our ...
Source: Mass Device - April 4, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Business/Financial News Mergers & Acquisitions News Well Research & Development catapultproductdevelopment smithwise Source Type: news

Advantia is on a buying spree. This time it ’s a local telehealth startup.
Arlington women ’s health group Advantia Health LLC has acquired D.C. telehealth startup Pacify Health Inc. The acquisition, announced Thursday, gives Advantia’s 430,000-patient network access to Pacify’s mobile platform, which connects them with maternal and pediatric specialists at all hours. Advantia is s hooting for its patients to have access to the Pacify platform this year. The companies declined to disclose deal terms. Advantia also filed a form with the Securities and Exchange Commission… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 4, 2019 Category: American Health Authors: Sara Gilgore Source Type: news

Is Walgreens CEO Pessina Opening Up To A Big Merger?
Walgreens Boots Alliance CEO Stefano Pessina says the drugstore chain is " constantly reviewing a certain number of companies. " (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 4, 2019 Category: Pharmaceuticals Authors: Bruce Japsen, Contributor Source Type: news

Supervisory Librarian, Collection Development and Acquisitions Section, Technical Services Division, Library Operations, NLM
This position will be posted on USAJOBS.gov from Thursday, April 4 – Monday, April 8, 2019. You will have an opportunity to shape the future of the National Library of Medicine (NLM)! NLM is implementing initiatives from its strategic plan, NLM Strategic Plan 2017-2027: A Platform for Biomedical Discovery and Data-Powered Health, and this position is expected to play a key role in providing high-quality services to the public and research communities. (Source: NLM General Announcements)
Source: NLM General Announcements - April 4, 2019 Category: Databases & Libraries Source Type: news

Practices'who do not get along' being forced into CCGs' preferred networks
CCGs are trying to force practices to form primary care networks without consideration for working relationships or GP opinions, according to a consultant for GP networks.  Consultant Scott McKenzie, who advises GPs on mergers, forming federations and now networks, told our sister publication Pulse, where this article was first published, that he has been inundated with questions from practices who are being pressured to form networks in a specific way by CCGs. Hide related content:  Show related contentread more (Source: Management in Practice)
Source: Management in Practice - April 4, 2019 Category: Practice Management Authors: costanzapearce Tags: *** Editor ' s Pick Latest News Source Type: news

Natus Medical deals Medix division to employees
Natus Medical (NSDQ:BABY) said yesterday that it inked a deal to sell its subsidiary Medix Medical Devices in an employee-led buyout. In the sale, Pleasanton, Calif.-based Natus Medical said it is offloading the Medix line of products including incubators and warmers. Natus said that Medix will continue to distribute the Medix products as well as the previously distributed line of Natus products and other third party products in Argentina and Venezuela. The separated Medix will also provide customer service, sales, customer support and warranty and repair services for the products. “This divestiture is an import...
Source: Mass Device - April 3, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Natus Medical Inc. Source Type: news

Acquisition could create dozens of jobs in South Florida
The buyer already has revenue of about $13 million. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 3, 2019 Category: Health Management Authors: Brian Bandell Source Type: news